ClinicalTrials.gg
RecruitingNCT07309055Updated Sep 8, 2026

A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis

A Phase 3 interventional study of SHR-1819 Injection and SHR-1819 Injection Placebo in Adolescents With Moderate-to-severe Atopic Dermatitis, sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Recruiting at 2 sites in China. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
201
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd. — 3 open to participants now, 5 under way, 2 of them phase 3. Dermatitis, Atopic · Jiangsu HengRui Medicine Co., Ltd..

Planned enrollment
4th of 14
201 · median 159
Started
2026
with 3 others
Phase 3
3 of 14
1 open now
Registered
12th of 14
by date

Among the 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd., this one is the 4th largest by planned enrollment, is one of 4 that started in 2026, is one of 3 in phase 3, and was the 12th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

3 of the 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This trial was designed to evaluate the efficacy and safety of SHR-1819 in adolescents with moderate-to-severe atopic dermatitis.

03

Conditions studied

  • Adolescents With Moderate-to-severe Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥12 to ≤17 years of age at time of screening visit, body weight ≥30kg;
  2. Diagnosis of Atopic Dermatitis (AD) at least 6 months prior to the screening visit according to the American Academy of Dermatology consensus criteria (Eichenfield 2014);
  3. Diagnosis of moderate to severe AD at the screening visit and baseline visits meet all of the following 3 criteria simultaneously: EASI ≥16, IGA ≥3, BSA≥10%;
  4. Baseline Pruritus Numerical Rating Scale (NRS) average score for maximum itch intensity ≥4 (A minimum of 5 daily scores out of the 7 days is required to calculate the baseline average score);
  5. With documented recent history (within 6 months before the screening visit) of inadequate response to topical AD medication(s) or for whom topical treatments is medically inadvisable (eg, intolerance, because of important side effects or safety risks). Patients with documented systemic treatment (systemic drugs like cyclosporine, methotrexate, etc.) for AD in the past 6 months are also considered as inadequate responders to topical treatments;
  6. Has applied a stable dose of topical emollient (moisturizer) twice daily for at least the 7 consecutive days immediately before the baseline visit;
  7. Participants and their parents/legal guardians voluntarily sign the form prior to the initiation of any study-related procedures, are able to communicate smoothly with the investigators, and understand and agree to strictly comply with the requirements of this clinical study protocol to complete the study.

Exclusion criteria

Exclusion Criteria:

  1. Has other active skin diseases (e.g., psoriasis or systemic lupus erythematosus) that may affect AD assessment, or skin complications caused by other diseases at screening visit;
  2. Has a history of vernal keratoconjunctivitis (VKC) and/or atopic keratoconjunctivitis (AKC) within 6 months prior to screening visit;
  3. Has received any of the following medications within 1 week prior to randomization: a) Topical (TCS) or topical calcineurin inhibitors (TCI); b) Topical traditional Chinese medicine (TCM) for atopic dermatitis; c) Other topical medications with therapeutic effects on AD (including but not limited to topical phosphodiesterase-4 [PDE-4] inhibitors, topical JAK inhibitors, etc.); d) Emollients containing active ingredients (e.g., ceramide, hyaluronic acid, urea, or filaggrin breakdown products); e) Leukotriene inhibitors (Note: If the participant is not taking such medications orally at randomization, they must have been off oral administration for at least 1 week prior to randomization; if the participant is taking such medications orally at randomization, they must have received stable-dose treatment for ≥2 weeks prior to randomization and continue stable use throughout the study period);
  4. Has received ≥2 bleach baths within 2 weeks prior to randomization;
  5. Has received any of the following treatments within 4 weeks prior to randomization: a) systemic glucocorticoids, (including but not limited to cyclosporine, azathioprine, methotrexate, etc.), or JAK inhibitors; b) Systemic traditional Chinese medicine (TCM) for atopic dermatitis (including but not limited to Tripterygium Glycosides Tablets, Compound Glycyrrhizin Tablets, etc.); c) Phototherapy (including but not limited to narrowband ultraviolet B [NB-UVB] and ultraviolet A1 [UVA1]) or regular use of tanning booths/room;
  6. Has received drugs or medical devices within 8 weeks prior to randomization or within 5 half-lives (if the half-life is known), whichever is longer;
  7. Has used biological products (including but not limited to anti-IL-4Rα monoclonal antibodies, anti-IgE monoclonal antibodies, anti-TSLP monoclonal antibodies, etc.) within 10 weeks prior to randomization or within 5 half-lives (if the half-life is known), whichever is longer;
  8. Has received or been exposed to other or attenuated live vaccines within 3 months prior to randomization, or participated in a vaccine clinical trial within 3 months prior to the first dose;
  9. Has received any cell-depleting agents (including but not limited to rituximab) within 6 months prior to randomization;
  10. Has received allergen-specific immunotherapy within 6 months prior to randomization;
  11. Has a current malignant tumor or history of malignant tumor at screening;
  12. Has undergone major surgery within 3 months prior to the first dose before randomization, or plans to undergo major surgery during the study period;
  13. Has severe comorbid diseases or other conditions deemed inappropriate for participation in the study by the investigator, including but not limited to endocrine diseases;
  14. Has been diagnosed with or deemed by the investigator to have suspected immunosuppressive diseases within 6 months prior to screening, including but not limited to non-tuberculous mycobacterial infection, history of opportunistic infections;
  15. Has a history of infection treated with systemic antimicrobials (for viral, bacterial, fungal, or parasitic infections) within 2 weeks prior to randomization, or has superficial skin infections (e.g., impetigo);
  16. Has a history of recurrent herpes zoster or Kaposi varicelliform eruption (≥ 2 episodes), disseminated herpes zoster, or disseminated herpes simplex within 1 year prior to screening;
  17. Suspected or confirmed active tuberculosis (TB);
  18. Positive results for (HIV) antibody, syphilis antibody, or virus (HCV) antibody;
  19. Presence of any of the following abnormalities in laboratory tests (including but not limited to HGB\WBC\Neutrophil\\AST\\) and/or 12-lead (ECG) within 4 weeks prior to randomization;
  20. Known to the study drug or any of its components.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
201 participants (estimated)

Study arms

  • Experimental
    SHR-1819 Injection Group with Dose 1

    Dose 1.

    Drug: SHR-1819 Injection

  • Placebo comparator
    SHR-1819 Injection Placebo Group with Dose 1

    Dose 1.

    Drug: SHR-1819 Injection Placebo

  • Experimental
    SHR-1819 Injection Group with Dose 2

    Dose 2.

    Drug: SHR-1819 Injection

  • Placebo comparator
    SHR-1819 Injection Placebo Group with Dose 2

    Dose 2.

    Drug: SHR-1819 Injection Placebo

Interventions

  • SHR-1819 injection.

  • DrugSHR-1819 Injection Placebo

    SHR-1819 injection placebo.

06

What researchers measure

Primary outcomes

  1. Proportion of patients with Eczema Area and Severity (EASI)-75.

    EASI-75: ≥ 75% improvement from baseline.

    Time frame: At week 16.

  2. Proportion of patients with an Investigator's Global Assessment (IGA) score of either 0 or 1.

    On a 5-point scale.

    Time frame: At week 16.

Secondary outcomes

  1. Proportion of patients with improvement (reduction) of weekly average of daily peak Pruritus Numerical Rating Scale (NRS) ≥ 4 from baseline to week 16.

    Time frame: From baseline up to week 16.

  2. Proportion of patients with Eczema Area and Severity (EASI)-90.

    EASI-90: ≥ 90% improvement from baseline.

    Time frame: At week 16.

  3. Proportion of participants achieving EASI-75 at week 1, 2, 4, 8, 12, 20, then every 4 weeks;

    Time frame: at week 1, 2, 4, 8, 12, 20, then every 4 weeks;

  4. Proportion of participants with an IGA score of 0 or 1.

    Time frame: at week 1, 2, 4, 8, 12, 20, then every 4 weeks;

  5. Proportion of patients with an Investigator's Global Assessment (IGA) score of a ≥ 2-point reduction from baseline.

    Time frame: at week 1, 2, 4, 8, 12, 20, then every 4 weeks

  6. The time from baseline to first achievement of EASI-75 by Week 16.

    Time frame: By Week 16.

  7. The time from baseline to first achievement of EASI-50 by Week 16.

    Time frame: By Week 16.

  8. The time from baseline to first achievement of EASI-90 by Week 16.

    Time frame: By Week 16.

  9. Proportion of participants achieving EASI-50 at week 1, 2, 4, 8, 12, 20, then every 4 weeks

    Time frame: at week 1, 2, 4, 8, 12, 20, then every 4 weeks

  10. Proportion of participants achieving EASI-90 at week 1, 2, 4, 8, 12, 20, then every 4 weeks

    Time frame: at week 1, 2, 4, 8, 12, 20, then every 4 weeks

  11. Change and percentage change in atopic dermatitis (AD)-affected body surface area (BSA) from baseline at week 1, 2, 4, 8, 12, 20, then every 4 weeks

    Time frame: at week 1, 2, 4, 8, 12, 20, then every 4 weeks

  12. Change and percentage change in Children's Dermatology Life Quality Index (CDLQI) score from baseline at week 1, 2, 4, 8, 12, 20, then every 4 weeks

    Time frame: at week 1, 2, 4, 8, 12, 20, then every 4 weeks

  13. Change and percentage change in Patient-Oriented Eczema Measure (POEM) score from baseline at week 1, 2, 4, 8, 12, 20, then every 4 weeks

    Time frame: at week 1, 2, 4, 8, 12, 20, then every 4 weeks

  14. Proportion of participants with a ≥ 2-point reduction in Investigator's Global Assessment (IGA) score from baseline at week 1, 2, 4, 8, 12, 20, then every 4 weeks

    Time frame: at week 1, 2, 4, 8, 12, 20, then every 4 week

07

Study locations

2 of 2 sites recruiting
  • The First Affiliated Hospital of China Medical University
    Shenyang, Liaoning 110002, China
    Recruiting
    • Xinghua Gao · Contactgaobarry@hotmail.com · +86-13940152467
    • Xinghua Gao · Principal investigator
  • Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine
    Shanghai, Shanghai Municipality 200092, China
    Recruiting
    • Zhirong Yao · Contactzryaoxh@sina.com · +86-021-25076428
    • Zhirong Yao · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Nov 2027, 20 months after the start.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's planned 20 months is above that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2025
First posted
Dec 30, 2025
StartActual
Mar 21, 2026
Primary completionEst.
Nov 2027
CompletionEst.
Dec 2027
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07309055
Responsible party
Sponsor
First posted
Dec 30, 2025
Start date
Mar 21, 2026
Primary completion
Nov 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Sep 8, 2026

Study contacts

Xiaoyan Bai
Contact
xiaoyan.bai.xb1@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Drotokibart

Start the discussion